Rituximab as monotherapy and in addition to reduced chop in children with primary immunodeficiency and non-hodgkin lymphoma

Shimrit Shabbat, Jonas Aharoni, Liat Sarid, Miriam Ben-Harush, Joseph Kapelushnik

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Children with primary immunodeficiency or chromosomal breakage syndromes are at increased risk of developing non- Hodgkin lymphomas; they cannot tolerate standard chemotherapy regimens. We report two children with diffuse, large, B-cell lymphoma; one had ataxia telangiectasia and one had common variable immunodeficiency. Both were given rituximab, 1 as monotherapy and 1 in combination with a reduced CHOP regimen. Complete remission was obtained in each patient. Use of rituximab as a first-line monotherapy or in conjunction with reduced chemotherapy should be considered to reduce cytotoxic effects.

Original languageEnglish
Pages (from-to)664-666
Number of pages3
JournalPediatric Blood and Cancer
Volume52
Issue number5
DOIs
StatePublished - 1 May 2009
Externally publishedYes

Keywords

  • Ataxia-telangiectasia
  • CHOP
  • CVID
  • NHL
  • Rituximab

Fingerprint

Dive into the research topics of 'Rituximab as monotherapy and in addition to reduced chop in children with primary immunodeficiency and non-hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this